Highlights
- Personalized therapy will evolve
- Each nanocarrier type’s unique features assist AD mitigation
- Existing animal models must be reviewed
Clinico-biochemical relation of Vitamin D3 with the severity of atopic dermatitis and response to supplementation of Vitamin D3: A randomized controlled trial
Source : https://mansapublishers.com/IJCH/article/view/3227
https://doi.org/10.32677/ijch.v8i12.3227 Atopy, Eczema, Vitamin D3, SCORAD, Pediatric Background: Atopic dermatitis (AD), also known as eczema, is one of the most common skin disorders among children and adults, with a steep...
Conclusion: Short-term therapeutic supplementation of Vitamin. D3 in children with moderate to severe AD improves the clinical score. There is an inverse relationship between serum Vitamin. D3 level and severity of AD.
Conclusion: A majority of existing literature confirmed a connection between low serum vitamin D levels and worsening of allergic reactions. However, there is weak evidence that supplementation (Cholecalciferol - 1000 IU) can improve these conditions. Further research needs to be conducted in order to establish the dose of Cholecalciferol for...
In our study, we found that ACE2 could be expressed in the skin, and its expression level is increased in psoriasis, an inflammatory disease of the skin with barrier dysfunction. Additionally, by applying the SARS-CoV-2 pseudovirus on mouse models with or without deteriorated skin barrier, we found that the SARS-CoV-2 pseudovirus could infect...
Uncommon variants in FLG2 and TCHHL1 are associated with remission of atopic dermatitis in a large longitudinal US cohort - Archives of Dermatological Research
Source : https://link.springer.com/article/10.1007/s00403-021-02319-7
Atopic dermatitis (AD) is a relapsing inflammatory skin disease; filaggrin (FLG) variation has been consistently associated with its pathogenesis. Filaggrin-2 (FLG2) and trichohyalin-like-1 (TCHHL1) are members of the same protein...
Twelve uncommon alleles in TCHHL1 trended toward association with increased AD remission (OR 23.46; 95% CI 7.07–77.89; adjusted p = 0.064). Among self-described African Americans, 13 uncommon FLG2 alleles were associated with increased AD remission (OR 21.01; 95% CI 11.90–37.09; adjusted p